NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.71 CHF | +0.25% |
|
-0.22% | +15.13% |
| Oct. 02 | NOVARTIS AG : Goldman Sachs reiterates its Neutral rating | ZD |
| Sep. 27 | ETF of the week: Value ready to bounce back? |  |
Summary: Novartis AG
- The company has a good ESG score relative to its sector, according to Refinitiv.
Highlights: Novartis AG
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses: Novartis AG
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 4.24 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings Chart: Novartis AG
Source: Surperformance
ESG chart: Novartis AG
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 230B | |||||
| 799B | |||||
| 507B | |||||
| 386B | |||||
| 343B | |||||
| 278B | |||||
| 242B | |||||
| 238B | |||||
| 172B | |||||
| 162B | |||||
| Average | 335.72B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
B-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NOVN Stock
- Ratings Novartis AG